Other
Journal
About P&T Journal
Contacts:Editor:
ssherritze@medimedia.com
Advertising:
mliberti@medimedia.com
Circulation:
lgardineer@medimedia.com
Production:
wpeart@medimedia.com
Rate Card
Production Specifications
Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints
Recent Issues
March 2012
Features
Tech Trends
FDA Weighs Updating Its Bar-Code Mandate
Hospital Pharmacies Worry About Implementation
Stephen Barlas
Controversies in Practice
Interviews With Two Women’s Health Experts on the Use of Estrogen Therapies
Two gynecologists share their views on hormone therapy.
Maribeth Maher
Multiple Sclerosis Review
Patients with relapsing–remitting multiple sclerosis now have a number of options—eight FDA-approved drugs, medications that relieve symptoms, and off-label therapies. Promising new agents are also under development.
Marvin M. Goldenberg, PhD, RPh, MS
Meeting Highlights
Cardiovascular Research Technologies 2012
Clopidogrel (Plavix) is prescribed more often than the newer antiplatelet agents ticagrelor (Brilinta) and prasugrel (Effient). Topics include the reasons behind the slow adoption of these two drugs, the best use of antiplatelet therapy, and considerations for switching patients from clopidogrel to the newer agents.
Walter Alexander
P&T Snapshot
Biologics and Specialty Pharmacy Health Care Survey
Implications for P&T Committees
Responding employers were generally uninformed about the benefits of biologics. Developing programs to help companies understand these products should enable them to manage costs more effectively and result in improved health outcomes for their insured employees.
Cheryl Larson, BA; Margaret Rehayem, MA; F. Randy Vogenberg, RPh, PhD; and Larry Boress, MPA
Departments
Medication Errors
Tall Man Letters Are Gaining Wide Acceptance
Tall man (capital) letters help prevent confusion of look-alike drug names.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Congress Is Likely to Approve Generic Drug User Fees
Action Should Spur Faster FDA Approvals
Congress may soon approve two new user-fee programs.
Stephen Barlas
Pharmaceutical Approval Update
Bydureon injection for diabetes, Onfi tablets for seizures in patients with Lennox–Gastaut syndrome, and Voraxaze injection for eliminating excessively high methotrexate levels in patients with renal impairment
Marvin M. Goldenberg, PhD, RPh, MS
New Drugs/Drug News/New Medical Devices
FDA approvals, drug indications, and updates
Drug Forecast
Roflumilast (Daliresp)
A Novel Phosphodiesterase-4 Inhibitor for the Treatment of Severe Chronic Obstructive Pulmonary Disease
Jordan Baye, PharmD, MA
